US Supreme Court mum on Teva vs Sandoz case

|About: Teva Pharmaceutical In... (TEVA)|By:, SA News Editor

No word on whether the Supreme Court will hear Teva Pharma's (TEVA -1.3%) patent case regarding the generic encroachment on its multiple sclerosis drug.

Predictably, Teva is keen to have its case reviewed in light of the US Court of Appeals verdict in July invaliding several of Copaxone's patents.

The case is, again, missing from the list of actionable cases published by the court today.

If it declines to pick up the matter generics could debut as early as May.